Apricus Biosciences Announces Closing of $3.55 Million Public Offering

NEXT STORY
CORRECTING and REPLACING – Precision Therapeutics Releases Highlights from FY 2017 Business Update Call
PREV STORY
Lux Research Releases In-Depth Benchmark Study on Sugar Replacement Technologies
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Sandoz receives European Commission approval for biosimilar Hyrimoz® (adalimumab)

Biosimilar Hyrimoz® (adalimumab) approved for use in all same indications as reference medicine*** including ...

author_avatar
NASDAQ Market News

VBL Therapeutics Announces Second Quarter 2019 Financial Results

author_avatar
NASDAQ Market News

ASLAN Pharmaceuticals to Present at HC Wainwright 20th Annual Global Investment Conference

SINGAPORE, Sept. 04, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical ...

author_avatar
NASDAQ Market News